China Sets 2030 Pharma Goals in 15th Five-Year Plan

China officially released its 15th Five-Year Plan for Pharmaceutical Industry Development on 18 September 2026, a strategic blueprint for 2026-2030 that, for the first time, elevates biopharmaceuticals to the status of a national “emerging pillar industry.” The plan was jointly issued by 10 government departments led by the Ministry of Industry and Information Technology (MIIT), according to Xinhua News.

At its core, the plan commits China to ranking among the world’s forefront in biomedical research and application by 2030, with systemic breakthroughs in key core technologies and a substantially upgraded competitive position globally. It sets 10 expected indicators that convert this ambition into measurable industrial targets.

What the Plan Targets

The headline economic goal is for above-scale pharmaceutical industrial enterprises to reach operating revenue of no less than 3.5 trillion yuan (approximately US$490 billion) by 2030. The plan also targets an average annual growth rate of at least 20% for innovative drugs, with the number of approved innovative drugs expected to rank among the world’s top.

A striking set of technology-specific targets underscores the plan’s innovation focus. First-in-class (FIC) novel drugs are to account for no less than 25% of the global total by 2030, while cumulative approved innovative medical devices must reach at least 200. The plan further aims for the number of products generating more than US$1 billion in global annual sales to reach at least five, and for 50 pharmaceutical enterprises to exceed 10 billion yuan in annual revenue. Twenty pharmaceutical industrial parks are expected to reach the 100 billion yuan scale.

As STCN (Securities Times) reported, the plan deploys 25 key tasks across eight areas. Beyond the headline indicators, it calls for listed pharmaceutical companies to maintain an average R&D investment intensity of at least 10% on an annual basis, strengthen original innovation capacity, and accelerate the development of first-in-class and best-in-class (BIC) drugs targeting new targets, mechanisms, and drug types.

Betting on Frontier Technology

The plan’s technology agenda stretches well beyond conventional drug development. It calls for accelerating the use of artificial intelligence, quantum computing, supercomputing, and computational medicine to empower drug discovery. It also explores novel manufacturing models including “extreme-limit manufacturing,” space-based pharmaceutical production, and biomanufacturing.

On the frontier-technology front, the plan identifies gene editing, precision molecular delivery, cell programming and regulation, advanced omics, and next-generation brain-computer interfaces as areas for deeper application. It also flags key technologies to be broken through, including artificial life-system synthesis, organoids and organ-on-chip platforms, universal cell therapies, complex regenerative organs, theranostic radiopharmaceuticals, and xenotransplantation organs.

This ambition rests on more than a decade of building. As Xueqiu analysis of the plan noted, China’s innovative drug approvals rose from 11 in 2015 to 92 in 2024, with the domestic share of innovative drug approvals climbing to 42%. The plan is designed to consolidate and extend that trajectory.

From Public Health to Economic Engine

The most consequential shift, analysts say, is the plan’s positioning of biopharmaceuticals as an emerging pillar industry—treating medicine not only as a public-health concern but as a core economic growth driver. Xueqiu’s analysis described this as a first: previous five-year plans had framed the sector around industrialisation, technology breakthroughs, and supply security, but the 15th Five-Year Plan formally elevates its strategic standing.

The backdrop is a sustained policy build-up. In May 2026, MIIT’s Wang Xiaoyang, Deputy Director of the Consumer Goods Industry Department, said the ministry was hastening compilation of the plan, framing it around four thrusts: “innovative medicine,” “inclusive medicine,” “digital-intelligent medicine,” and “open medicine.” He added that ocean-based drugs and functional products would be included as a key development field, as Huxiu reported at the time.

Parallel initiatives have reinforced the approach. In 2025, seven departments issued an implementation plan for the digital-intelligent transformation of the pharmaceutical industry covering 2025-2030. And in July 2026, the State Council approved a separate 15th Five-Year Plan for traditional Chinese medicine revitalisation, which notably listed AI as a core technological pathway for TCM. The earlier 14th Five-Year Plan for the pharmaceutical industry, issued for 2021-2025, had focused on innovation-driven transformation, supply security, and internationalisation—goals the new plan now builds upon and widens.

Coordinated Implementation

MIIT signalled that implementation would be coordinated across government. The ministry said it would strengthen the role of inter-ministerial coordination mechanisms, aligning industrial, science and technology, regulatory, medical, health-insurance, financial, and talent policies. It also committed to optimising review and approval mechanisms and refining pricing, payment, and usage policies.

That coordination is central to the plan’s health-economics context. Xueqiu’s analysis noted that provincial-level pooling of medical insurance funds—designed to break down administrative barriers between cities and channel surplus funds to regions facing aging populations or fund shortfalls—could help resolve structural imbalances and revive spending growth, framing it as a potential new starting point for pharmaceutical investment.

What to Watch

The plan’s scale reflects both ambition and risk. Analysts cited by Xueqiu flagged several uncertainties: weaker-than-expected pharmaceutical consumption if macroeconomic pressure persists, policy shortfalls in innovative drug insurance payment, global order shifts driven by geopolitics, and sharper-than-expected price cuts from centralised procurement or fee reductions.

Beyond those risks, the plan’s success will hinge on execution. Meeting a 25% share of global first-in-class drugs by 2030 would represent a dramatic leap in original innovation, moving China beyond its historical strengths in generics and me-too development. Whether the coordinated policy apparatus—spanning R&D, review, payment, and internationalisation—can deliver on that promise will define the next five years for one of the world’s largest pharmaceutical markets.

For now, the signal is unambiguous: China is treating the biopharmaceutical industry as a strategic growth engine, and it is backing that bet with a decade of policy groundwork and a set of hard, public targets.